Cite
HARVARD Citation
Hamilton, E. et al. (n.d.). Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). European journal of cancer. pp. S36-. [Online].